ArticleFrontiers in medicine2026
Case Report: Infantile hypercalcemia type 1 due to CYP24A1 pathogenic variants-three adult patients with nephrolithiasis and nephrocalcinosis successfully treated with fluconazole.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hypercalcemia type 1 (HCINF1) is a rare genetic disorder caused by pathogenic variants in the CYP24A1 gene, which encodes the vitamin D-catabolic enzyme 24-hydroxylase responsible for inactivating 1,25-dihydroxyvitamin D₃. The clinical presentation ranges from severe forms diagnosed in infancy-characterized by hypercalcemia, dehydration, and vomiting-to milder forms that are often identified in adulthood during evaluation for recurrent nephrolithiasis. We present two adult female patients with late-onset HCINF1, both initially referred to a nephrologist for nephrolithiasis and nephrocalcinosis, and one male patient with an infantile presentation who began fluconazole therapy in adulthood. This case series highlights rare late-onset manifestations of HCINF1 associated with recurrent nephrolithiasis, secondary distal renal tubular acidosis (dRTA), and variable degrees of renal function impairment. It emphasizes the importance of considering genetic testing in adults with unexplained hypercalcemia and nephrolithiasis and supports the therapeutic role of fluconazole in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.